Menu Search
Equities

Huakang Biomedical Holdings Co Ltd

8622:HKG.HZ

Huakang Biomedical Holdings Co Ltd

Actions
  • Price (HKD)0.116
  • Today's Change-0.002 / -1.69%
  • Shares traded4.25m
  • 1 Year change-39.90%
  • Beta--
Data delayed at least 15 minutes, as of Jul 04 2024 08:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Huakang Biomedical Holdings Co Ltd is an investment holding company mainly engaged in the production and sales of in-vitro diagnostic reagents. The Company operates its business through two segments. The Biological Reagents and Auxiliary Reproductive Supplies and Equipment segment is engaged in the research and development, production, marketing and sales of in-vitro diagnostic reagents, including male infertility in vitro diagnostic reagents, parasite series detection reagents and Epstein-Barr (EB) virus detection reagents. The Segment is also engaged in the manufacture and sale of auxiliary reproductive supplies and devices. The Healthcare Products and Supplements segment is engaged in the sales of health products and supplements.

  • Revenue in HKD (TTM)26.47m
  • Net income in HKD-6.21m
  • Incorporated2017
  • Employees96.00
  • Location
    Huakang Biomedical Holdings Co Ltd2/F, 100 Des Voeux Road Central, Central Hong KongHKG
  • Phone+852 22028989
  • Fax+852 22028989
  • Websitehttp://www.huakangbiomedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.